Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer‐related death primarily due to the lack of effective targeted therapies. Despite the distinct morphological and phenotypic patterns of HCC, treatment strategies are restricted to relatively homogeneous therapies, including multitargeted tyrosine kinase inhibitors and immune checkpoint inhibitors. Therefore, more effective therapy options are needed to target dysregulated...